 Planning to initiate rolling BLA submission for omidubicel following positive Type B meeting with FDA Full BLA submission on track for first half of 2022 BOSTON--BUSINESS WIRE-- Gamida Cell Ltd. Nasdaq: GMDA, an advanced cell therapy company committed to cures for cancer and other serious diseases, announced that following receipt of positive Type B meeting correspondence from the U.S. Food and Drug Administration FDA yesterday, the company plans to initiate a rolling Biologics License Application BLA submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant. 